用于治疗多发性肌炎和皮肌炎相关间质性肺病的生物制剂
Biologics in polymyositis and dermatomyositis-associated interstitial lung disease.
作者信息
Sun Yuechi, He Yan, Liu Yuan, Shi Guixiu
机构信息
Department of Rheumatology, The First Affiliated Hospital, Xiamen University, No. 55, Zhenhai Road, Xiamen 361003, China.
出版信息
Curr Pharm Biotechnol. 2014;15(6):521-4. doi: 10.2174/138920101506140910145940.
Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.
间质性肺疾病（ILD）是多发性肌炎（PM）和皮肌炎（DM）最常见的并发症之一。它通常呈进行性发展，对传统免疫抑制剂治疗无反应。生物制剂常用于治疗风湿性疾病，也用于治疗与多发性肌炎和皮肌炎相关的间质性肺疾病。本综述将聚焦于生物制剂在PM/DM-ILD中的最新应用。
Zotero 插件